Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.

Saved in:
Bibliographic Details
Title: Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.
Authors: Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Dunbar A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kugler E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shpall EJ; Department of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Popat U; Department of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ramdial J; Department of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Champlin RE; Department of Stem Cell Transplant & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Senapati J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Source: Cancer [Cancer] 2026 May 15; Vol. 132 (10), pp. e70434.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70434